Olaparib is an anti-cancer drug which comes under N-acyl piperazines class. The action of olaparib is PRPA inhibition. Drug taken by oral route which shows action in 1 to 3 hrs. after administration. It is FDA approved drug for various cancer treatment such as ovarian cancer, breast cancer, prostatic cancer and pancreatic cancer. Olaparib also useful different mutation conditions such as BRCA1/2 mutation. Olaparib prescribes after the chemotherapy treatment either singly or in combination. In serious and advanced mutation conditions combination therapy used. In this review paper, we put a narrative information about olaparib action, treatment approaches, pharmacokinetics, dosing regimen and resistance. Here we briefly give information about resistance mechanism of olaparib, treatment approaches in ovarian cancer, breast cancer and prostate cancer.
CITATION STYLE
Rohit Deepak Nalawade, & Bhagwan Dilip Devkar. (2021). Olaparib an anticancer drug: A review. World Journal of Advanced Research and Reviews, 11(2), 329–336. https://doi.org/10.30574/wjarr.2021.11.2.0406
Mendeley helps you to discover research relevant for your work.